相关实验视频
Updated: Jun 13, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
548
心力衰竭中的达帕格利弗洛辛:对功能能力,症状和安全结果的全面元分析
Basilio Addo1, Walter Agyeman2, Sammudeen Ibrahim2
1Department of Internal Medicine, Piedmont Athens Regional Medical Center, 1199 Prince Avenue, Athens, GA, 30606, USA. basilioaddo@yahoo.com.
概括
达帕格利弗洛辛显著改善了心力衰竭患者的生活质量 (KCCQ分数),并减少了住院治疗. 虽然在统计学上不显著,但功能能力 (6分钟步行距离) 显示出积极的趋势,在减少喷射小部分患者中观察到死亡率的好处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 心力衰竭 (HF) 仍然是全球住院和死亡的主要原因.
- 现有的高频疗法存在局限性,需要新的治疗策略.
- 作为SGLT2抑制剂的达帕格利弗洛辛在治疗高血压方面表现有前途,但其对功能能力和安全性的影响需要对高血压亚型进行详细评估.
研究的目的:
- 为了在心力衰竭患者中比较达帕格利弗洛辛与安慰剂的影响.
- 评估达帕格利弗洛辛对功能能力,症状和安全结果的影响.
- 为了研究达帕格利弗洛辛在心力衰竭中对保存 (HFpEF) 和减少喷射率 (HFrEF) 群体的疗效.
主要方法:
- 对随机对照试验 (RCT) 进行了系统的元分析.
- 在主要的数据库中进行了搜索:PubMed,科学网,柯克兰图书馆和Scopus.
- 主要结局包括6分钟步行距离 (6MWD) 和堪萨斯城心肌病问卷 (KCCQ) 得分的变化,以及住院,死亡率和不良事件等安全措施.
主要成果:
- 达帕格利弗洛辛显著改善了KCCQ得分 (RR 2.75,p < 0.00001),但没有显著改变6MWD (RR 3.59,p = 0.16).
- 观察到心力衰竭住院病例 (RR 0.76,p < 0.00001) 和所有原因死亡率 (RR 0.90,p = 0.03) 的显著减少.
- 在达帕格利弗洛辛和安慰剂组之间没有发现不良事件的显著差异 (RR 0.96,p = 0.39).
结论:
- 在HFrEF和HFpEF患者中,达帕格利弗洛辛显著提高了生活质量 (KCCQ分数).
- 该药物在所有患者类别中显示出在减少心力衰竭住院的显著益处.
- 虽然功能能力 (6MWD) 没有达到统计学意义,但观察到有利于达帕格利弗洛辛的趋势,以及HFrEF患者的死亡率益处.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
01:22Heart Failure Drugs: Diuretics
350
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
350
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inotropic Agents
543
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
543
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
01:22Heart Failure Drugs: β-Blockers
321
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321